Orange Book record for REVLIMID (lenalidomide) capsules, NDA 021880 (2026)

Government Record · U.S. Food and Drug Administration, Orange Book · November 13, 2026

U.S. Food et al., 2026-11-13: Orange Book product record for Revlimid showing approval on 27 December 2005 and Bristol Myers Squibb as applicant holder; FDA's accompanying patent data file lists US 7,465,800 (expires 2027-04-27) and US 8,741,929 (expires 2028-03-08) against this NDA.

Approval Date: Dec 27, 2005

HTML record, unpaginated

U.S. Food et al., 2026-11-13: Orange Book product record for Revlimid showing approval on 27 December 2005 and Bristol Myers Squibb as applicant holder; FDA's accompanying patent data file lists US 7,465,800 (expires 2027-04-27) and US 8,741,929 (expires 2028-03-08) against this NDA. Funder/conflicts: n/a. Maker: Bristol Myers Squibb (Celgene). Comparator: n/a. The web page renders product and approval data but not the patent table (it is delivered by script); patent numbers and expiry dates above come from FDA's Orange Book patent.txt data file downloaded the same day (fda.gov/media/76860/download), not from the rendered page. First lenalidomide ANDA recorded by FDA: 201452, approved 21 May 2021. Study type: regulatory record.